Freespira

Digital therapeutics are primed for growth. The market is expected to reach 178M users this year and is projected to exceed $32.5B by 2030. This space is ripe for engagement and investment, but the path to value is murky for health systems, payers, and solution companies. This webinar will define the capability, describe what good looks like, and unpack insights into how different healthcare players can tap into the action.

Digital therapeutics, also called DTx, is a digital capability that exists within the broader category of digital medicine. DTx solutions are evidence-based, clinically validated and scalable software applications used to treat, manage, and/or prevent a variety of diseases and disorders in order to improve health outcomes and reduce costs. In addition, solutions are provider-prescribed, include privacy and security protections, and have received approval from the appropriate regulatory bodies.

The Top Digital Therapeutics Companies Report is intended to provide healthcare leaders with a broad view of digital patient education and showcase standout companies and solutions with proven market traction. Users can view quick summaries to help them identify which solutions might meet their needs and visit AVIA Marketplace to access detailed profiles and verified client lists, compare solutions, and generate Match Scores to narrow their selections. This report is powered by AVIA Marketplace data, and inclusion is based on the number of verified health system clients listed for each company on AVIA Marketplace. Due to confidentiality agreements, vendors may not always be able to provide full lists of clients.